WO2007009404A1 - Formulaciones nasales de eporh con bajo contenido de ácido siálico para el tratamiento de enfermedades del sistema nervioso central. - Google Patents
Formulaciones nasales de eporh con bajo contenido de ácido siálico para el tratamiento de enfermedades del sistema nervioso central. Download PDFInfo
- Publication number
- WO2007009404A1 WO2007009404A1 PCT/CU2006/000007 CU2006000007W WO2007009404A1 WO 2007009404 A1 WO2007009404 A1 WO 2007009404A1 CU 2006000007 W CU2006000007 W CU 2006000007W WO 2007009404 A1 WO2007009404 A1 WO 2007009404A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- eporh
- sialic acid
- epo
- formulations
- nasal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to the Biopharmaceutical Industry and in particular to the production of a medicament for nasal administration of EPOrh with low content of sialic acid (basic) from Chinese hamster ovary cells by genetic engineering for the treatment of cerebrovascular, neurodegenerative and psychiatric diseases.
- Erythropoietin is a glycoprotein hormone whose molecular weight ranges around 34kDa; The protein fraction consists of approximately 166 amino acids; It occurs in the kidney, liver and cells of the central nervous system and is involved in the proliferation, differentiation and maturation of erythrocytes and other hematopoietic cells.
- the neuroprotective effects of EPOrh may be due to different factors within which they are: antagonism of glutamate-induced cytotoxicity, increase in the expression of antioxidant enzymes, decrease in the formation of free radical-mediated nitric oxide (NO), normalization of cerebral blood flow, influence on the release of neurotransmitters, promotion of neoangiogenesis, inhibition of apoptosis induced by excitotoxins and NO, increase in the expression of antiapoptotic genes, neurotropic effect, decrease in neuronal excitability, cerebral anti-inflammatory effect, inhibition of The apoptosis induced by kainate and the production of proinflammatory atokines, angiogenic and neurogenic effect and contributes to ischemic preconditioning and as a whole can justify the use of EPOrh in the treatment of cerebrovascular, neurodegenerative and psychiatric diseases.
- antagonism of glutamate-induced cytotoxicity increase in the expression of antioxidant enzymes
- EPOrh can prevent or reverse the neuronal death characteristic of many diseases of the central nervous system, such as ischemia, neurotrauma, and neurodegenerative and neuroinflammatory diseases.
- neurodegenerative processes contribute to the triggering of the pathophysiology of schizophrenia, which is why neuroprotective drugs can be an effective therapeutic alternative for the treatment of this disease.
- the CIPO-2074820 patent uses the nasal route for the administration of the protein, in this case cyclodextrin is used as a component of the formulation and also pursues a systemic absorption of EPO, so the protein also has to be acidic.
- the CIPO-2353553 patent justifies the exogenous administration of the EPO for the treatment of cerebral ischemia, but as in the previous cases it is pursued that the protein passes directly or indirectly to the bloodstream to be effective, so that we are also in presence of EPO with high sialic acid content.
- the CIPO-2408685 patent protects different EPO formulations, but its use is intended for the treatment of anemia, which is why it is acidic EPO, since the basic EPO does not promote the proliferation, differentiation and maturation of erythrocytes.
- the CIPO-2437333 patent specifies that the protected formulations are from epoetin alfa, that is to say acid EPO.
- This formulation can be used for the treatment and / or prevention of diseases of the central nervous system including cerebrovascular, neurodegenerative and psychiatric disorders, on an outpatient basis at the level of primary health care.
- the advantages of the proposed solution include the use of EPOrh with low sialic acid content for therapeutic purposes allowing a greater protective effect with lower doses.
- a rapid arrival at the site of action is achieved, which is critical when it comes to achieving a therapeutic effect against cerebral hypoxia.
- the therapeutic window period In the specific case of cerebrovascular diseases, in the acute phase it is necessary to start the therapeutic intervention before certain processes of the ischemic cascade have occurred, which is called the therapeutic window period.
- the nasal route of administration of basic EPOrh eliminates the risk of inducing erythropoiesis.
- An increase in the concentration of erythrocytes increases the viscosity of the blood and compromises reperfusion after an occlusive or hemorrhagic episode, decreases cerebral blood flow and therefore hinders the arrival of oxygen and nutrients to the tissue.
- the nasal route has greater advantages than other forms of administration, allowing rapid access to the brain, it is less invasive than the intravenous or intracerebroventricular one and a percentage of the EPOrh can reach the cerebrospinal fluid without having to pass the bloodstream before avoiding the hepatic first-pass metabolism and consequently its inactivation.
- the nasal application route is not traumatic and eliminates surgical risks or other possible implications given by traumatic routes. It constitutes an alternative route of access to the brain without damaging the blood brain barrier.
- the use of an alternative route to the vascular route ensures the arrival of the molecule to poor or non-irrigated areas of the central nervous system, by diffusion through the interstitial fluid.
- bioadhesive polymers that increase the residence time of the EPOrh in Ia is followed as a strategy in this invention.
- Nasal Cavity During the development of the formulation, other auxiliary substances or excipients are also incorporated, such as preservative substances, surfactants, pH regulators, isotonic agents and protein stabilizers; to obtain a stable physicochemical and microbiological formulation that maintains its therapeutic properties over time.
- An EPOrh was used that contained in its molecule less than 40% sialic acid (basic) at a concentration from 0.5 to 2 mg / mL.
- the formulations presented are liquid, colorless, transparent and free of mechanical impurities preparations with an apparent viscosity that ranges from 10 to 250 mPas using hydroxypropylmethylcellulose (HPMC) as bioadhesive polymers in concentrations from 0.4 to 0.9%, hydroxypropylcellulose , (HPC) 0.2 to 0.8% and methylcellulose (MC) from 0.25 to 0.5%.
- HPMC hydroxypropylmethylcellulose
- the pH was adjusted in a range from 6.0 to 7.5 using mainly phosphate buffers and citrates in concentrations of 20 to 100 mM / L.
- Osmotic pressure can be regulated with different isotonizers among which are: sodium chloride, mannitol, sorbitol, glucose, among others, in a range of 0.05 to 10 g / L
- the preservative agents were: benzalkonium chloride of 0.01 to 0.02% in combination with disodium EDTA in concentrations of 0.01%, chlorobutanol of 0.3 to 0.5%, methylparaben of 0.02 to 0.035% and propylparaben of 0.01 to 0.02%.
- nonionic surface active substances such as polyethylene sorbitan laurate (tween 20 to 80), cremofor RH 40, sorbitan trioleate (spam 35 to 80) were used, in a range of concentrations between 0.01 and 1 g / L.
- Different amino acids were used as protein stabilizers, among which are: L-tryptophan, L-leucine, L-arginine hydrochloride and L- hydrochloride histidine in a concentration range between 0.1 and 10 mg / mL
- the solvent used in all cases was water for injection.
- a nasal buffer solution of NaH 2 PO 4 and Na 2 HPO 4 was used at a pH of 6.0 and a conductivity of 3.25 ms / cm.
- the pH was controlled using a Sartorius pH meter and an Omega conductimeter.
- the process performance is in a range between 75 - 95%. Table 1 shows the results obtained in the process:
- EPOrh nasal formulation with low sialic acid content that uses HPMC bioadhesive polymer, histidine hydrochloride as a stabilizer, Tween 80 as a surface active substance and benzalkonium chloride as a preservative.
- the preparation of the solution it is based on a volume of water for injection that represents 30% of the total volume of the formulation, it preserves the buffer, the buffers and the isotonizing agent. Moreover in a container of suitable capacity 15% of the total volume of the formulation of water for injection they are incorporated and heated 85-95 0 C, pulverizing the polymer with stirring strong and constant. Once the polymer has been wetted, the previously prepared solution is incorporated thereto with vigorous stirring until total homogenization. The agitation is reduced for the incorporation of the corresponding volume of basic EPOrh, the superficially active substance and the protein stabilizer, finally it is flush with water for injection to a final volume that represents 100% of the formulation. The formulation is filtered through a 0.2 ⁇ m cellulose acetate membrane and it is verified that the pH is maintained in the established range.
- the composition of the finished form is as follows:
- composition of the finished form is as follows:
- EPOrh nasal formulation with low sialic acid content similar to example 2 but with Tween 20 as a superficially active substance.
- composition of the finished form is as follows:
- composition of the finished form is as follows:
- composition of the finished form is as follows:
- the preparation of the solution it is based on a volume of water for injection that represents 30% of the total volume of the formulation, in it the buffers are solubilized and the agent toner. Moreover in a container of suitable capacity 15% of the total volume of the formulation of water for injection are incorporated and heated between 90-95 0 C, the parabens are dissolved and the polymer incorporated by stirring strong and constant. Once the polymer has been wetted, the previously prepared solution is added thereto with vigorous stirring until total homogenization. The agitation is reduced for the incorporation of the corresponding volume of basic EPOrh, the superficially active substance and histidine hydrochloride and finally it is flush with water for injection to a final volume that represents 100% of the formulation. Subsequently, the formulation is filtered through a 0.2 ⁇ m cellulose acetate membrane and it is verified that the pH is maintained in the established range.
- composition of the finished form is as follows:
- EPOrh nasal formulation with low sialic acid content similar to the previous example but with methylcellulose as bioadhesive polymer.
- composition of the finished form is as follows:
- composition of the finished form is as follows:
- composition of the finished form is as follows:
- Example 12 Nasal formulation of EPOrh with low sialic acid content similar to example 7 but with chlorobutanol as an antimicrobial preservative.
- composition of the finished form is as follows:
- composition of the finished form is as follows:
- EPOrh nasal formulation with low sialic acid content similar to example 12 but with Tween 20 as a superficially active substance.
- composition of the finished form is as follows:
- composition of the finished form is as follows:
- Example 16 "In vitro" evaluation of the stimulatory action on cells of nervous origin of the nasal formulation of recombinant human erythropoietin with a low content of sialic acid
- GST Glutathione-S-Transferase
- PC12 cells The cells were maintained undifferentiated in DMEM medium supplemented with 2 mM L-Glutamine, 100 Units / ml penicillin G, 100 micrograms / ml streptomycin (GIBCO), 10% (v / v) containing 1OmM Hepes Buffer. In the culture 10% total horse serum was used.
- the homogenate thus obtained was kept in an ice bath and was used for the determination of the specific activity of the GST according to the Habig method. (Habig, WH, Pabst, JJ, and Jakoby, WB 1974; Biol. Chem. 249 (22): 7130-7139). Protein determination was performed by the Bradford method (Bradford MM. Anal. Biochem, 72, (176) 158). As a main result, it was obtained that the cells of nervous origin responded to the presence of the EPO by modifying the activity of the GST enzyme.
- the plotted values (Fig. 1) represent the average value of three independent crops.
- This graph shows the action of acid and basic erythropoietin on the enzymatic activity of GST in PC12 cell culture. In this graph we can observe how the cells of nervous origin respond to the presence of the EPO by modifying the activity of the GST enzyme. The response with recombinant human Erythropoietin with low sialic acid and acid content was similar.
- Mongolian gerbils of both sexes were used, with a body weight between 60 and 70 grams, with water and ad limitum feeding, which were maintained in a 12-hour alternating cycle of light-dark throughout the experimental period.
- the unilateral permanent occlusion (ULP) of the right carotid of the animals was performed, under deep anesthesia, for which the intraperitoneal route was used, as a diazepan pre-anesthetic (5.0 mg / Kg.); as a ketamine anesthetic (47 mg / kg) and 0.02 mg / kg of Atropine.
- the right carotid was exposed under stereoscope, doubly linked and sectioned.
- the falsely injured animals were obtained with the same manipulations but without binding or cutting the carotid.
- the treatment consisted of the application in the nasal cavity of 10 ⁇ l of EPOrh or its vehicle every 8 h daily, from 1 hour after the operation until the 4th. day after the operation.
- the spontaneous exploratory activity was also used, where the steepness on the hind legs that the rodents make when exploring a new vessel were counted.
- a vertical cylindrical box 30 cm in diameter and 25 cm high was used as a container. Each gerbil was placed in the center of that box and the steepings were counted in an interval of 3 minutes.
- the animals were perfused through the left ventricle with 4% formaldehyde in phosphate buffer solution (PBS) at pH 7.0. Brains were extracted and maintained in this solution for a few days. They were subsequently included in paraffin, sectioned at 4 ⁇ m and stained with hematoxylin and eosin. The sections were evaluated at 10x and 4Ox, without prior knowledge of their identity.
- PBS phosphate buffer solution
- FIG. 3 we can see the motor behavior of the gerbil of Mongolia in the cylinder. Significant functional damage appears in injured animals without treatment. Exploratory-motor activity appears depressed in untreated ischemic animals while in those treated with EPOrh, it remains similar to that of controls.
- Figure 4 shows the neurological state of the animals 24 hours after the injury. The effect of the lesion and treatment with EPOrh by nasal route in the model of permanent unilateral ischemia on the body weight of the animals after 5 weeks is shown in Figure 5. The group of injured animals compared with the injured and treated groups or falsely injured showed a different weight curve behavior. Similar curves were obtained in the control and injured group treated, contrasting with the weight loss of the injured and untreated animals. This group could not exceed the average weight with which the experiment began.
- Figure 8 shows M icrofotog raffias of the Gerbil hippocampus treated with EPOrh by nasal route.
- the integrity of the CA1 sector in the treated animals can be noted.
- pichnosis was observed throughout the right hemisphere as well as hemorrhages in the fimbria of the right hippocampus and in the parietal cortex of the right hemisphere, areas of edema, dense and diffuse chromatin in the right hemisphere. Pycnotic neurons in the hippocampus.
- Example 18 Example 18:
- the animals were sacrificed by cervical dislocation and decapitation, the brain was quickly removed from the cranial cavity and the tissue was immediately frozen at -70 degrees celcius.
- the hippocampus, cerebral cortex and cerebellum regions of each animal were dissected with the help of a stereotactic atlas (Paxinos, G., and Watson, C. (1986). Academic Press, New York, pp 230-259).
- a pool of each of these regions was formed and a homogenate of each region was prepared containing 1: 8 parts of tissue by 0.1 M phosphate buffer pH 7.0.
- the cell-free liquid was obtained by centrifugation at 4 degrees celcius at 10,000 g for 30 minutes.
- the presence of the labeled molecule in regions of the cerebellum indicates the passage of the BHE, on the other hand, the detection of the molecule at the level of regions not related to the olfactory pathway (cerebellum) indicates that not only the olfactory pathway is compromised in the passage of molecules to the brain, but a more general and rapid mechanism is participating, which can be diffusion through the mucus and subsequent permeation through discontinuities that occur in regions of the olfactory epithelium, particularly in the area of the cribriform sheet , which allows the arrival of recombinant human erythropoietin with low content of sialic acid to regions far from the olfactory pathway.
- Figure 11 represents the passage through the nasal route of the recombinant human erythropoietin with low sialic acid content to olfactory bulb and cerebellum.
- the figure represents in each bar the average value of six animals. It shows how recombinant human erythropoietin with low sialic acid content reaches regions of the brain in at least 5 minutes and over time it gradually decreases from the frontal region at caudal. After 60 minutes of application, there is still EPO in the olfactory bulb and cerebellum regions. Between 80 and 85% of the EPO that reaches the brain was detected in the olfactory bulbs, while about 20% was detected in the cerebellum after 5 minutes of application. After 30 minutes these concentrations almost equalize and after 60 minutes the cerebellum has 30% and only 10% of the radioactivity of the olfactory bulb.
- the test was carried out in male New Zealand rabbits with a weight between 3-4 Kg that were anesthetized with intramuscular ketamine 40 mg / kg, subsequently 5 ml of blood were extracted from the central artery of the ear that were percutaneously injected into the magna cistern , the animals were monitored for 72 h.
- the rabbits were divided into 3 experimental groups with 8 animals each: Group I: Non-injured animals Group II: Injured animals
- Group III Injured animals + basic EPOrh 20 ⁇ g (example 5) The administrations of basic EPOrh were performed, 5 minutes after inducing the suranoid hemorrhage and repeated every 8 hours for 72 hours.
- the degree of neurological damage was classified as: 1: There are no indications of damage. 2: Minimal damage.
- the right carotid under anesthesia was linked to 36 glands in Mongolia and treated with 40 ul daily of EPOrh by nasal route (examples 10 and 11) for 7 days, beginning within 1 hour after surgery. Another 24 animals received similar processing and an equivalent amount of vehicle was administered. To 9 gérbiles the carotid was isolated without ligating it and constituted the control group.
- the results show a smaller slope (closer to 0) in animals undergoing ischemia, one week after ischemia and in comparison with those treated with EPOrh and controls.
- a smaller slope demonstrates a persistence of the animal in exploring this environment in the last two thirds, showing a loss of habituation that can be characterized as a cognitive dysfunction induced by ischemia.
- the treatment with basic EPOrh prevents the onset of this dysfunction.
- the behavior of the animals revealed a deterioration induced by the ischemia that could be expressed in a loss of the ability to nest, typical in males of this species, in an increase in aggressiveness and in a loss of the grooming behavior during the time they remained in the circular cylinder.
- the results were compared using the chi-square independence test and were expressed in the table in percent:
- the behavioral deterioration can be described as a reflection of the neuronal loss and other histopathological findings observed in the untreated group.
- the treatment with EPOrh prevents at least partially the behavioral deterioration induced by the decrease in cerebral blood flow in the gerbil of Mongolia.
- the results are relevant in the sense of suggesting a neuroprotective action of EPO rh capable of counteracting the functional deterioration of dementia of vascular origin in man.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0615541-3A BRPI0615541A2 (pt) | 2005-07-22 | 2006-07-27 | formulaÇÕes nasais de eritropoietina recombinante humana (rhuepo) com baixo conteédo de Ácido siÁlico para o tratamento de doenÇas do sistema nervoso central |
ES06761631.8T ES2682619T3 (es) | 2005-07-22 | 2006-07-27 | Formulaciones nasales rh-EPO con concentración de ácido siálico para el tratamiento de enfermedades del sistema nervioso central |
CA2616156A CA2616156C (en) | 2005-07-22 | 2006-07-27 | Nasel formulations of recombinant human erythropoietin (rhepo) with low content of sialic acid for the treatment of diseases of the central nervous system |
EP06761631.8A EP1997483B1 (en) | 2005-07-22 | 2006-07-27 | Rh-epo nasal formulations with low sialic acid concentration for the treatment of diseases of the central nervous system |
AU2006272217A AU2006272217A1 (en) | 2005-07-22 | 2006-07-27 | Rh-epo nasal formulations with low sialic acid concentration for the treatment of diseases of the central nervous system |
MX2008000997A MX2008000997A (es) | 2005-07-22 | 2006-07-27 | Formulaciones nasales de eporh con bajo contenido de acido sialico para el tratamiento de enfermedades del sistema nervioso central. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2005-0138 | 2005-07-22 | ||
CU20050138A CU23317A1 (es) | 2005-07-22 | 2005-07-22 | Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007009404A1 true WO2007009404A1 (es) | 2007-01-25 |
Family
ID=40122422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2006/000007 WO2007009404A1 (es) | 2005-07-22 | 2006-07-27 | Formulaciones nasales de eporh con bajo contenido de ácido siálico para el tratamiento de enfermedades del sistema nervioso central. |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1997483B1 (es) |
CN (2) | CN105435212A (es) |
AU (1) | AU2006272217A1 (es) |
BR (1) | BRPI0615541A2 (es) |
CA (1) | CA2616156C (es) |
CU (1) | CU23317A1 (es) |
HK (1) | HK1216993A1 (es) |
MX (1) | MX2008000997A (es) |
TR (1) | TR201815428T4 (es) |
WO (1) | WO2007009404A1 (es) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017220053A1 (es) | 2016-06-20 | 2017-12-28 | Centro De Inmunologia Molecular | Uso de la forma básica de la eritropoyetina humana recombinante en el tratamiento de pacientes con ataxia espinocerebelosa con mutaciones del tipo repeticiones cag |
WO2021043345A1 (es) | 2019-09-05 | 2021-03-11 | Centro De Inmunologia Molecular | Eritropoyetina humana recombinante hiposialilada, métodos de purificación y usos terapéuticos de esta |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3021871A1 (en) | 2013-07-17 | 2016-05-25 | Dow Global Technologies LLC | Composition for application to a mucosa comprising a methylcellulose |
CN104730070A (zh) * | 2015-03-19 | 2015-06-24 | 邢海霞 | 一种联合检测唾液酸和羟脯氨酸的试剂及其检测方法 |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57146710A (en) | 1981-03-07 | 1982-09-10 | Kunio Yagi | Blood brain-barrier permeating ribosome-like microcapsule |
US4639437A (en) | 1983-11-08 | 1987-01-27 | Fidia, S.P.A. | Kit or device and method for administering gangliosides and derivatives thereof by inhalation and pharmaceutical compositions suitable therefor |
GB2177914A (en) * | 1985-06-04 | 1987-02-04 | Chugai Pharmaceutical Co Ltd | Erythropoietin compositions |
US4801575A (en) | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
WO1989001343A1 (en) | 1987-08-17 | 1989-02-23 | The Regents Of The University Of California | Cationized antibodies for delivery through the blood-brain barrier |
JPH01149718A (ja) | 1987-12-07 | 1989-06-12 | Yoshikatsu Eto | 脳血液関門を通過し易いリポゾーム製剤 |
EP0504263A1 (en) | 1989-12-05 | 1992-09-23 | Ramsey Foundation | NEUROLOGICAL ACTIVE SUBSTANCES FOR NASAL ADMINISTRATION TO THE BRAIN. |
US5260308A (en) | 1991-11-06 | 1993-11-09 | Mayo Foundation For Medical Education And Research | Method to increase permeability of the blood-nerve/brain barriers to proteins |
US5442043A (en) | 1992-11-27 | 1995-08-15 | Takeda Chemical Industries, Ltd. | Peptide conjugate |
JPH08231417A (ja) | 1994-12-28 | 1996-09-10 | Chugai Pharmaceut Co Ltd | エリスロポエチンのリポソーム製剤 |
WO2003004475A1 (en) | 2001-07-05 | 2003-01-16 | Astrazeneca Ab | Heterocyclic amines for the treatment of conditions associated with gsk-3 |
WO2004002402A2 (en) * | 2002-05-21 | 2004-01-08 | Nastech Pharmaceutical Company Inc. | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
US20040122216A1 (en) * | 2002-07-01 | 2004-06-24 | Jacob Nielsen | Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs |
WO2005004895A2 (en) * | 2003-06-09 | 2005-01-20 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of growth hormone |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9001987D0 (en) * | 1990-01-29 | 1990-03-28 | Janssen Pharmaceutica Nv | Improved cyclodextrin based erythropietin formulation |
DE69930509T2 (de) * | 1998-07-08 | 2006-11-30 | Kirin-Amgen Inc., Wilmington | Pulverförmiges präparat zur anwendung auf schleimhäuten welches ein polymeres arzneimittel enthält |
-
2005
- 2005-07-22 CU CU20050138A patent/CU23317A1/es unknown
-
2006
- 2006-07-27 EP EP06761631.8A patent/EP1997483B1/en active Active
- 2006-07-27 BR BRPI0615541-3A patent/BRPI0615541A2/pt not_active IP Right Cessation
- 2006-07-27 CN CN201510674598.7A patent/CN105435212A/zh active Pending
- 2006-07-27 CN CNA200680034781XA patent/CN101296692A/zh active Pending
- 2006-07-27 CA CA2616156A patent/CA2616156C/en active Active
- 2006-07-27 WO PCT/CU2006/000007 patent/WO2007009404A1/es active Application Filing
- 2006-07-27 MX MX2008000997A patent/MX2008000997A/es active IP Right Grant
- 2006-07-27 TR TR2018/15428T patent/TR201815428T4/tr unknown
- 2006-07-27 AU AU2006272217A patent/AU2006272217A1/en not_active Abandoned
-
2016
- 2016-04-29 HK HK16104978.0A patent/HK1216993A1/zh unknown
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57146710A (en) | 1981-03-07 | 1982-09-10 | Kunio Yagi | Blood brain-barrier permeating ribosome-like microcapsule |
US4639437A (en) | 1983-11-08 | 1987-01-27 | Fidia, S.P.A. | Kit or device and method for administering gangliosides and derivatives thereof by inhalation and pharmaceutical compositions suitable therefor |
GB2177914A (en) * | 1985-06-04 | 1987-02-04 | Chugai Pharmaceutical Co Ltd | Erythropoietin compositions |
US4801575A (en) | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
WO1989001343A1 (en) | 1987-08-17 | 1989-02-23 | The Regents Of The University Of California | Cationized antibodies for delivery through the blood-brain barrier |
JPH01149718A (ja) | 1987-12-07 | 1989-06-12 | Yoshikatsu Eto | 脳血液関門を通過し易いリポゾーム製剤 |
EP0504263A1 (en) | 1989-12-05 | 1992-09-23 | Ramsey Foundation | NEUROLOGICAL ACTIVE SUBSTANCES FOR NASAL ADMINISTRATION TO THE BRAIN. |
US5260308A (en) | 1991-11-06 | 1993-11-09 | Mayo Foundation For Medical Education And Research | Method to increase permeability of the blood-nerve/brain barriers to proteins |
US5442043A (en) | 1992-11-27 | 1995-08-15 | Takeda Chemical Industries, Ltd. | Peptide conjugate |
JPH08231417A (ja) | 1994-12-28 | 1996-09-10 | Chugai Pharmaceut Co Ltd | エリスロポエチンのリポソーム製剤 |
WO2003004475A1 (en) | 2001-07-05 | 2003-01-16 | Astrazeneca Ab | Heterocyclic amines for the treatment of conditions associated with gsk-3 |
WO2004002402A2 (en) * | 2002-05-21 | 2004-01-08 | Nastech Pharmaceutical Company Inc. | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
US20040122216A1 (en) * | 2002-07-01 | 2004-06-24 | Jacob Nielsen | Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs |
WO2005004895A2 (en) * | 2003-06-09 | 2005-01-20 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of growth hormone |
Non-Patent Citations (7)
Title |
---|
"Canadian Council for Animal Protection", vol. 1, 1998, article "Handbook of Care and Use of Experimental Animals" |
BRADFORD, ANAL MM. BIOCHEM, vol. 72, no. 176, pages 158 |
ERBAYRAKTAR S. ET AL.: "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo", PNAS, vol. 100, no. 11, 27 May 2003 (2003-05-27), pages 6741 - 6747, XP009070746 * |
HABIG, W.H.; PABST, J.J.; JAKOBY, W.B., BIOL. CHEM., vol. 249, no. 22, 1974, pages 7130 - 7139 |
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 127, 1996, pages 115 - 133 |
PAXINOS, G.; WATSON, C.: "Academic Press", 1986, pages: 230 - 259 |
SOSA-TESTE ET AL.: "Intranasal administration of recombinant human erythropoietin exerts neuroprotective effects on post-ischemic brain injury in mongolian gerbils", PHARMACOLOGYONLINE, vol. 1, pages 100 - 112, XP003005912, Retrieved from the Internet <URL:http://www.pharmacologyonlines.unisa.it/archivies/2006/volue1/8_sosaTeaste.pdf> * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017220053A1 (es) | 2016-06-20 | 2017-12-28 | Centro De Inmunologia Molecular | Uso de la forma básica de la eritropoyetina humana recombinante en el tratamiento de pacientes con ataxia espinocerebelosa con mutaciones del tipo repeticiones cag |
WO2021043345A1 (es) | 2019-09-05 | 2021-03-11 | Centro De Inmunologia Molecular | Eritropoyetina humana recombinante hiposialilada, métodos de purificación y usos terapéuticos de esta |
Also Published As
Publication number | Publication date |
---|---|
EP1997483B1 (en) | 2018-07-18 |
CN105435212A (zh) | 2016-03-30 |
HK1216993A1 (zh) | 2016-12-16 |
TR201815428T4 (tr) | 2018-11-21 |
EP1997483A4 (en) | 2014-05-21 |
EP1997483A1 (en) | 2008-12-03 |
AU2006272217A1 (en) | 2007-01-25 |
CU23317A1 (es) | 2008-10-22 |
CA2616156C (en) | 2016-07-19 |
BRPI0615541A2 (pt) | 2013-02-13 |
CA2616156A1 (en) | 2007-01-25 |
MX2008000997A (es) | 2008-03-14 |
CN101296692A (zh) | 2008-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10702582B2 (en) | HGF preparation suitable for treatment of neurological disorders | |
ES2472737T3 (es) | Usos m�dicos adicionales de la proteína antisecretora | |
EA007967B1 (ru) | Защита, восстановление и усиление эритропоэтинреактивных клеток, тканей и органов | |
EP3238746B1 (en) | High-density lipoprotein, and delivery of drug to posterior segment of eye by ocular instillation of said cytophilic peptide-fused high-density lipoprotein | |
EP3270889B1 (en) | Targeted liposomal delivery of cgmp analogues | |
CA2650132C (en) | Modulation of lipid rafts | |
US20200071372A1 (en) | C-terminal CDNF and MANF fragments, pharmaceutical compositions comprising same and uses thereof | |
WO2007009404A1 (es) | Formulaciones nasales de eporh con bajo contenido de ácido siálico para el tratamiento de enfermedades del sistema nervioso central. | |
US9226951B2 (en) | Anti-tumor fibrillar human serum albumin methods and compositions | |
ES2247329T3 (es) | Prevencion de muerte celular utilizando segmentos de proteinas fibrilares neurales. | |
ES2789723T3 (es) | Composiciones que comprenden CDNF para usar en el tratamiento intranasal de enfermedades del sistema nervioso central | |
ES2370790A1 (es) | Uso de oxalacetato en el tratamiento de isquemia. | |
ES2682619T3 (es) | Formulaciones nasales rh-EPO con concentración de ácido siálico para el tratamiento de enfermedades del sistema nervioso central | |
EP1948217B1 (en) | Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease | |
GB2414934A (en) | Treatment of Parkinson's disease with GDNF | |
US10143722B2 (en) | Application of YB-1 protein and fragments thereof for preparing medicinal agents in treating alzheimer's disease | |
JPH0491034A (ja) | 中枢神経保護剤 | |
CN114555630A (zh) | 用于治疗脊髓损伤和/或髓鞘再生的肽的全身施用 | |
US11970521B2 (en) | Neuroprotective beta amyloid core peptides and peptidomimetic derivatives | |
AU2013200099A1 (en) | NASAL FORMULATIONS OF RECOMBINANT HUMAN ERYTHROPOIETIN (rhEPO) WITH LOW CONTENT OF SIALIC ACID FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | |
KR102079953B1 (ko) | 키토산 코팅 및 내부에 담지된 피코시아닌을 포함하는 리포좀 및 이를 포함하는 비강 투여용 뇌질환 치료용 약학적 조성물 | |
Sosa et al. | Recombinant human erythropoietin as a neuroprotective therapy in brain ischemia | |
KR20230057747A (ko) | 세포사멸 억제 단백질을 포함하는 허혈성 뇌졸중 예방 또는 치료용 조성물 | |
WO2021183407A1 (en) | Norrin regulation of plasmalemma vesicle-associated protein and use to treat macular degeneration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680034781.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2008521781 Country of ref document: JP Ref document number: 2616156 Country of ref document: CA Ref document number: MX/a/2008/000997 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006761631 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006272217 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2006272217 Country of ref document: AU Date of ref document: 20060727 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006272217 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: PI0615541 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080122 |